HCW Biologics (HCWB) AGM 2025 summary

Opening remarks and agenda

• Meeting commenced with a welcome and acknowledgment of forward-looking statements and associated risks, referencing recent SEC filings for risk factors.

• CEO highlighted recent achievements since the last special meeting, including compliance with Nasdaq listing rules.

Financial performance review

• Raised $5.5 million to fund immunotherapeutics development.

• Converted $6.6 million of debt to equity, improving the balance sheet.

• Recognized $7 million in revenue in Q2 2025 from a technology report acceptance.

Board and executive committee updates

• Introduced non-employee directors and executive staff present at the meeting.

• Inspector of Election and external advisors were also in attendance.